Compare OZK & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZK | LQDA |
|---|---|---|
| Founded | 1903 | 2004 |
| Country | United States | United States |
| Employees | 3351 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | N/A | 2020 |
| Metric | OZK | LQDA |
|---|---|---|
| Price | $53.01 | $73.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $55.00 | $41.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $12.84 | $278.87 |
| Revenue Next Year | $6.32 | $57.13 |
| P/E Ratio | ★ $8.01 | $148.37 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $42.37 | $14.25 |
| 52 Week High | $53.66 | $82.96 |
| Indicator | OZK | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 51.10 |
| Support Level | $45.99 | $70.85 |
| Resistance Level | N/A | $82.96 |
| Average True Range (ATR) | 1.14 | 4.50 |
| MACD | 0.06 | -1.30 |
| Stochastic Oscillator | 90.95 | 30.34 |
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides banking services, including checking, savings, money market, time deposits, and individual retirement accounts, as well as loan services, such as real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services, it also provides trust and wealth management, financial planning, online banking, and other related services.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.